Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Dipyridyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | CCR1 | P32246 | 3/20 | 0.88 |
| ▸ | CCR5 | P51681 | 3/20 | 0.88 |
| ▸ | CCR8 | P51685 | 3/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.88 |
| ▸ | POLB | P06746 | 1/20 | 0.88 |
| ▸ | METAP1 | P53582 | 1/20 | 0.88 |
| ▸ | BLM | P54132 | 1/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.88 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.88 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.88 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL8594903 | 1.00 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL2371023 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL1237608 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL8716183 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL7909040 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3799914 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL15136892 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL497901 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL18065641 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL31634369 | 0.97 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112608208-A | Synthetic method for preparing gamma-cyanoolefin by decarboxylation at room temperature | 滁州学院 | 2021-04-06 | — | — | CN | claimed |
| WO-2024109702-A1 | BRAIN OXYGEN MONITORING SYSTEM, INTRACRANIAL MONITORING SYSTEM, AND METHOD | 深圳湃诺瓦医疗科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-115611816-A | Method for efficiently preparing 5-aryl (hetero) ring modified uracil derivative | 中国科学院化学研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-112608208-A | Synthetic method for preparing gamma-cyanoolefin by decarboxylation at room temperature | 滁州学院 | 2021-04-06 | — | — | CN | disclosed |
| US-6702986-B1 | TRIPROPYLAMINE, BUFFERING ELECTROLYTE, SURFACTANT AND WATER | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6562789-B2 | Free radical scavenger in cosmetics, drugs | L'OREAL S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020165165-A9 | New histidine derivatives, preparation process, and their use as free antiradical agents | L'OREAL S.A. | 2002-11-07 | — | — | US | disclosed |
| US-6451225-B1 | MIXTURES OF CHELATE COMPOUNDS, AMINES AND ELECTROLYTES USED FOR CHEMICAL AND QUANTITATIVE ANALYSIS; DETECTION OF ELECTROMAGNETIC RADIATIONS EMITTED; ACCURACY | IGEN INTERNATIONAL, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20010031732-A1 | New histidine derivatives, preparation process, and their use as free antiradical agents | L'OREAL S.A. | 2001-10-18 | — | — | US | disclosed |
| US-6271041-B1 | FORMING MIXTURE CONTAINING METAL-CONTINING ELECTROCHEMILUMINESCENT MOIETY; AMINE OR AMINE COMPOUNDAND ELECTROLYTE; EXPOSING TO ELECTROCHEMICAL ENERGY SO THAT ELECTROCHEMILUMINESCENCE IS EMITTED; DETECTING LUMINESCENCE | IGEN INTERNATIONAL, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-0697107-B1 | ELECTROCHEMILUMINESCENT PROCESS | BOEHRINGER MANNHEIM GMBH (DE) | 1998-01-07 | — | — | EP | disclosed |
| EP-0441894-B1 | ELECTROCHEMILUMINESCENT REACTION UTILIZING AMINE-DERIVED REDUCTANT | IGEN INC (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0441875-B1 | ENHANCED ELECTROCHEMILUMINESCENCE | IGEN INC (US) | 1997-07-09 | — | — | EP | disclosed |
| EP-0697106-B1 | ELECTROCHEMILUMINESCENT PROCESS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-04-02 | — | — | EP | disclosed |
| EP-0441894-A4 | ELECTROCHEMILUMINESCENT REACTION UTILIZING AMINE-DERIVED REDUCTANT | — | 1992-09-16 | — | — | EP | disclosed |
| EP-0441875-A4 | ENHANCED ELECTROCHEMILUMINESCENCE | — | 1992-03-11 | — | — | EP | disclosed |
| EP-0441875-A1 | ENHANCED ELECTROCHEMILUMINESCENCE. | IGEN INC (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0441894-A1 | ELECTROCHEMILUMINESCENT REACTION UTILIZING AMINE-DERIVED REDUCTANT | IGEN, INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| WO-1990005302-A1 | ENHANCED ELECTROCHEMILUMINESCENCE | IGEN, INC. (US) | 1990-05-17 | — | — | WO | disclosed |
| WO-1990005296-A1 | ELECTROCHEMILUMINESCENT REACTION UTILIZING AMINE-DERIVED REDUCTANT | IGEN, INC. (US) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031732-A1 | New histidine derivatives, preparation process, and their use as free antiradical agents | HRH1, HRH4, H1-0 | KDM4E 2546/4885LMNA 2055/4885CCR1 2507/4885 |
| US-20020165165-A9 | New histidine derivatives, preparation process, and their use as free antiradical agents | HRH1, HRH4, H1-0 | KDM4E 2546/4885LMNA 2055/4885CCR1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.